FIA
PCVX icon

FNY Investment Advisers’s Vaxcyte PCVX Stock Holding History

FNY Investment Advisers’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Hold
2,000
– – 0.04% 303
2026
Q1 		$116K Hold
2,000
– – 0.05% 258
2025
Q4 		$92K Hold
2,000
– – 0.03% 350
2025
Q3 		$72K Buy
+2,000
New +$66.3K 0.02% 433

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

FNY Investment Advisers's PCVX Position: Q2 2026 in Review

FNY Investment Advisers held its Vaxcyte (PCVX) position steady in Q2 2026 at 2,000 shares worth $116K. The position accounts for 0.04% of the portfolio, ranked #303.

FNY Investment Advisers first reported a position in PCVX in Q3 2025 and has held it in 4 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • FNY Investment Advisers held 2,000 shares of Vaxcyte worth $116K as of Q2 2026.
  • FNY Investment Advisers left its Vaxcyte share count unchanged in Q2 2026.
  • Vaxcyte made up 0.04% of FNY Investment Advisers's portfolio in Q2 2026, its #303 holding.
  • FNY Investment Advisers first reported a position in Vaxcyte in Q3 2025 and has held it in 4 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.